Hanna Betsy 4
Research Summary
AI-generated summary
TREACE (TMCI) Director Betsy Hanna Receives 30,000-Share RSU Award
What Happened
- Betsy Hanna, a director of Treace Medical Concepts, Inc. (TMCI), was granted 30,000 restricted stock units (RSUs) on May 19, 2026. The award was reported as an acquisition at $0.00 (i.e., a compensation grant rather than a purchase).
- The RSUs represent the right to receive one share of TMCI common stock per RSU upon vesting; no immediate cash or share sale occurred. This is a compensation/retention award rather than an open-market buy or sale.
Key Details
- Transaction date: 2026-05-19. Transaction code: A (award/grant).
- Amount: 30,000 RSUs; reported acquisition price: $0.00 (grant).
- Vesting: 100% vesting on the earlier of (a) May 19, 2027 or (b) the date of the 2027 annual meeting, subject to continued service (Footnote F1).
- Deferral: Hanna voluntarily elected to defer receipt of the underlying shares until a change in control or her separation of service (Footnote F1).
- Footnote F2 confirms the 30,000 RSUs included in the filing.
- Shares owned after the transaction are not specified in the provided filing. The Form 4 was filed the same day (timely).
Context
- RSUs are a form of equity compensation that convert to shares upon vesting; they do not represent an immediate cash position and are common for directors and executives as retention/incentive grants.
- Because this is a grant (not a purchase or sale), it should be viewed as compensation-related rather than a direct market sentiment signal.